TG TherapeuticsTGTX +4.10%82 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $58.22 (Fairly Valued). The stock has 8 warning signs investors should review. Among 145 Biotechnology companies, TG Therapeutics ranks worse than 689654.48% on this metric.
As of today (2026-06-28), the Forward Annual Dividend Yield of TG Therapeutics is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of TG Therapeutics is 0.00%.
TGTX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
TG Therapeutics Forward Dividend Yield % Related Terms
TGTX vs SRRK, COGT, RYTM: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, TG Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
TG Therapeutics (TGTX) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TG Therapeutics and its competitors. According to the industry distribution chart, TG Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry.
Is TG Therapeutics' Forward Dividend Yield % too high?
TG Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, TG Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Forward Dividend Yield % compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #999999 out of 145 companies for Forward Dividend Yield %. This places TG Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TG Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $58.22, compared to a current price of $55.81 — trading 4.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (TGTX) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued.
The current stock price of $55.81 is trading 4.1% below its estimated GF Value™ of $58.22.
GuruFocus considers TG Therapeutics to be Fairly Valued.
Key valuation signals for TGTX:
Forward Dividend Yield %: 0.00%
GF Value™: $58.22 vs. price of $55.81 (4.1% below fair value)
No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score
Get the complete analysis for TGTX
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGTX has been successfully added to your 